CN1997383B - 含水母发光蛋白的组合物及使用它的方法 - Google Patents

含水母发光蛋白的组合物及使用它的方法 Download PDF

Info

Publication number
CN1997383B
CN1997383B CN200580024585XA CN200580024585A CN1997383B CN 1997383 B CN1997383 B CN 1997383B CN 200580024585X A CN200580024585X A CN 200580024585XA CN 200580024585 A CN200580024585 A CN 200580024585A CN 1997383 B CN1997383 B CN 1997383B
Authority
CN
China
Prior art keywords
aequorin
calcium
acid
compositions
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN200580024585XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1997383A (zh
Inventor
M·Y·安德伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quincy Bioscience LLC
Original Assignee
Quincy Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience LLC filed Critical Quincy Bioscience LLC
Publication of CN1997383A publication Critical patent/CN1997383A/zh
Application granted granted Critical
Publication of CN1997383B publication Critical patent/CN1997383B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
CN200580024585XA 2004-06-21 2005-06-21 含水母发光蛋白的组合物及使用它的方法 Expired - Lifetime CN1997383B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/872,795 2004-06-21
US10/872,795 US20060229243A1 (en) 2004-06-21 2004-06-21 Aequorin-containing compositions and methods of using same
PCT/US2005/021770 WO2006010004A2 (en) 2004-06-21 2005-06-21 Aequorin-containing compositions and methods of using same

Publications (2)

Publication Number Publication Date
CN1997383A CN1997383A (zh) 2007-07-11
CN1997383B true CN1997383B (zh) 2011-01-05

Family

ID=35785748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580024585XA Expired - Lifetime CN1997383B (zh) 2004-06-21 2005-06-21 含水母发光蛋白的组合物及使用它的方法

Country Status (20)

Country Link
US (3) US20060229243A1 (https=)
EP (2) EP2545934B1 (https=)
JP (1) JP4971150B2 (https=)
KR (1) KR101213555B1 (https=)
CN (1) CN1997383B (https=)
AU (1) AU2005265266B2 (https=)
BR (1) BRPI0512392B1 (https=)
CA (1) CA2571542C (https=)
CY (1) CY1114307T1 (https=)
DK (1) DK1768691T3 (https=)
ES (1) ES2422173T3 (https=)
IL (1) IL180195A (https=)
MX (1) MXPA06015037A (https=)
NZ (1) NZ552274A (https=)
PL (1) PL1768691T3 (https=)
PT (1) PT1768691E (https=)
SG (1) SG153848A1 (https=)
SI (1) SI1768691T1 (https=)
WO (1) WO2006010004A2 (https=)
ZA (1) ZA200610688B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same
GB0625678D0 (en) 2006-12-21 2007-01-31 Lux Biotechnology Ltd Composition and method for detection of demineralisation
BRPI0909435A2 (pt) 2008-03-11 2017-06-13 Quincy Bioscience Llc composição e método para tratar de um sintoma ou distúrbio associado com o desequilíbrio do cálcio, uso da apoequorina, e, apoaequorina
JP2010143860A (ja) * 2008-12-19 2010-07-01 Chisso Corp タンパク質の安定化剤
US20110130336A1 (en) * 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
US9316588B2 (en) * 2010-12-24 2016-04-19 Otsuka Pharmaceutical Co., Ltd. Bioassay method for detecting physiologically active substance
KR102009932B1 (ko) * 2011-11-15 2019-08-12 퀸시 바이오사이언스 엘엘씨 허혈로 인한 뉴런 손상을 감소시키기 위한 아포에쿼린
GB201700317D0 (en) 2017-01-09 2017-02-22 Calcivis Ltd Detection device
USD1042180S1 (en) 2020-05-28 2024-09-17 Calcivis Limited Dental detection device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001240855A (ja) * 2000-03-01 2001-09-04 Masashi Sugimoto 生物発光方法及び発光物品
WO2001096361A1 (en) * 2000-06-12 2001-12-20 University Of Maryland Biotechnology Institute Method of controlling the binding of calmyrin to presenilin
US20060229243A1 (en) * 2004-06-21 2006-10-12 Quincy Resource Group, Inc. Aequorin-containing compositions and methods of using same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800492B2 (en) * 2000-06-01 2004-10-05 Institute Pasteur Chimeric GFP-aequorin as bioluminescent Ca++ reporters at the single cell level

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAUBET等.Chimeric green fluorescent protein-aequorin as bioluminescentCa2+ reporters at the single-cell level.Proc.Natl.Acad.Sci.97 13.2000,97(13),第7260-7265页.
BAUBET等.Chimeric green fluorescent protein-aequorin as bioluminescentCa2+ reporters at the single-cell level.Proc.Natl.Acad.Sci.97 13.2000,97(13),第7260-7265页. *
MITHOFER等.Aequorin-based measurements of intracellularCa2+-signatures in plant cells.Biological Procedures4 1.2002,4(1),第105-118页.
MITHOFER等.Aequorin-based measurements of intracellularCa2+-signatures in plant cells.Biological Procedures4 1.2002,4(1),第105-118页. *
姜云飞等.测定血小板胞浆游离钙中水母发光蛋白导入液的重复应用.中华血液学杂志12 2.1991,12(2),第96-97页.
姜云飞等.测定血小板胞浆游离钙中水母发光蛋白导入液的重复应用.中华血液学杂志12 2.1991,12(2),第96-97页. *

Also Published As

Publication number Publication date
ZA200610688B (en) 2007-12-27
CN1997383A (zh) 2007-07-11
IL180195A0 (en) 2007-06-03
EP1768691A4 (en) 2010-08-04
CA2571542A1 (en) 2006-01-26
WO2006010004A2 (en) 2006-01-26
CY1114307T1 (el) 2016-08-31
AU2005265266B2 (en) 2011-05-12
NZ552274A (en) 2010-06-25
US7671015B2 (en) 2010-03-02
JP2008503581A (ja) 2008-02-07
EP2545934A1 (en) 2013-01-16
HK1109576A1 (en) 2008-06-13
IL180195A (en) 2014-03-31
US20080287350A1 (en) 2008-11-20
AU2005265266A1 (en) 2006-01-26
JP4971150B2 (ja) 2012-07-11
BRPI0512392B1 (pt) 2022-12-13
DK1768691T3 (da) 2013-07-01
EP2545934B1 (en) 2014-12-10
EP1768691A2 (en) 2007-04-04
US20060229243A1 (en) 2006-10-12
CA2571542C (en) 2014-08-19
SI1768691T1 (sl) 2013-07-31
PT1768691E (pt) 2013-06-20
WO2006010004A3 (en) 2007-03-08
BRPI0512392A (pt) 2008-03-11
EP1768691B1 (en) 2013-05-22
ES2422173T3 (es) 2013-09-09
PL1768691T3 (pl) 2013-09-30
KR20070070154A (ko) 2007-07-03
MXPA06015037A (es) 2007-07-11
SG153848A1 (en) 2009-07-29
US20100152117A1 (en) 2010-06-17
KR101213555B1 (ko) 2012-12-18

Similar Documents

Publication Publication Date Title
US8367116B2 (en) Buoyant polymer particles for delivery of therapeutic agents to the central nervous system
EP3505161B1 (en) Sublingual pharmaceutical composition of edaravone and (+)-2-borneol
WO2008040260A1 (es) Uso del factor de crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
CN1997383B (zh) 含水母发光蛋白的组合物及使用它的方法
KR101643662B1 (ko) 아포에쿼린 함유 조성물 및 이의 사용 방법
CN108143719A (zh) 一种携载多肽的纳米脂质体及其制备方法和应用
CN103664936A (zh) 一类治疗创伤性脑损伤疾病的化合物及其用途
CN1256949C (zh) 三七总皂苷脂质体及其制备方法
CN115120611B (zh) 一种no供体型胶束组合物及其制备方法与应用
JPH07165582A (ja) 免疫抗癌剤の抗癌効果増強剤
CN109496152A (zh) 癸氧喹酯组合物的肌肉内库存及其预防和治疗的方法
TWI921816B (zh) 一種生物複合體與其衍生之微胞複合物及其製備方法
JPS63303931A (ja) 経鼻投与用成長ホルモン放出活性物質製剤
CN112451475B (zh) 一种用于治疗空洞型肺结核的长效缓释凝胶
Starr Innovations in drug delivery.
CN100364610C (zh) 提高蚓激酶口服吸收生物利用度的方法
JP2001514671A (ja) 癌治療薬
CN121197021A (zh) 一种细菌外囊泡负载活性成分的复合微针及其制备方法和应用
KR102494794B1 (ko) 여성 성기능장애의 치료를 위한 약학 조성물 및 방법
CN103664954A (zh) 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103664798A (zh) 一类治疗创伤性脑损伤疾病的化合物及其用途
US20200078438A1 (en) Agent for the Treatment of Skin Wounds or Burns
CN103655572A (zh) 一类治疗创伤性脑损伤疾病的化合物及其用途
CN103655575A (zh) 一类治疗创伤性脑损伤疾病的化合物及其用途
Pillay et al. Polymeric intracorporeal devices for the management of neurological disorders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1109576

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1109576

Country of ref document: HK

CX01 Expiry of patent term

Granted publication date: 20110105

CX01 Expiry of patent term